DelistingApr 28, 2026, 05:02 PM
CTOR Receives Nasdaq Delisting Notice for Bid Price Rule Violation
AI Summary
Citius Oncology, Inc. received a notice from Nasdaq on April 22, 2026, indicating non-compliance with the minimum $1.00 bid price requirement for continued listing. The company's common stock traded below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). CTOR has 180 calendar days, until October 19, 2026, to regain compliance by having its stock close at $1.00 or more for at least ten consecutive business days. The notice does not immediately affect the stock's listing, and the company is evaluating its options.
Key Highlights
- CTOR received a Nasdaq notice on April 22, 2026, for failing the $1.00 minimum bid price rule.
- The company's common stock traded below $1.00 for 30 consecutive business days.
- CTOR has 180 calendar days, until October 19, 2026, to regain compliance.
- Compliance requires the bid price to close at $1.00 or more for a minimum of ten consecutive business days.
- Failure to comply may lead to an additional 180-day period or delisting.